Extending the resistance axis, proteomic studies identify glyoxalase 1 (Glo1) overexpression as a key contributor to multidrug resistance in breast cancer by detoxifying methylglyoxal and suppressing apoptosis. This evidence concerns the gene GLO1 and breast cancer.